Chinese burn: new blacklists to expose healthcare company misbehaviour
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies that value their reputation in China will soon need to tread more carefully when it comes to keeping in line with local drug and device laws. From 1 October a new blacklist will publically expose misbehaving companies and their misdemeanours for patients and healthcare professionals to see.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.